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Abstract
Background: The main study objectives were: to develop a set of requirements of comprehensive breast centres; to
establish a nationwide voluntary certification programme for breast centres based on such requirements, a certified
quality management system (QMS), and scheduled independent, external audits and periodic recertification; and to
demonstrate the general acceptance of such a certification programme with a view to introducing similar certification
programmes for other major cancers.
Methods: Breast centres introduced a QMS and voluntarily participated in an external certification procedure based on
guideline-derived Requirements of Breast Centres specifically developed for the application procedure, all subsequent
audits and recertification. All data (numbers of pending and successful applications, sites/centre, etc.) were collected by
a newly founded, independent organisation for certification of cancer services delivery. Data analysis was descriptive.
Results: Requirements of Breast Centres were developed by the German Cancer Society (DKG), the German Society
of Senology (DGS) and other relevant specialist medical societies in the form of a questionnaire comprising 185 essential
items based on evidence-based guidelines and the European Society of Breast Cancer Specialists' (EUSOMA)
requirements of specialist breast units. From late 2002 to mid 2008, the number of participating breast centres rose from
1 to 175. As of mid 2008, 77% of an estimated 50,000 new breast cancers in Germany were diagnosed and treated at
certified breast centres, 78% of which were single-site centres.
Conclusion: Nationwide voluntary certification of breast centres is feasible and well accepted in Germany. Dual
certification of breast centres that involves certification of breast services to guideline-derived requirements in
conjunction with independent certification of a mandatory QMS can serve as a model for other multidisciplinary site-
specific cancer centres.
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Background
Breast cancer, like many other malignancies, is regarded
today as a systemic disease requiring multimodal, multi-
disciplinary treatment to achieve the best possible out-
comes [1,2]. In recent years, the provision of evidence-
based cancer care and the implementation and mainte-
nance of quality assurance procedures have moved into
the centre of attention as two key areas of modern multi-
disciplinary oncology [3].
In this context, the quest for strategies to reduce breast
cancer morbidity and mortality has focused on the setting
required for the optimal treatment of breast cancer
because epidemiological and clinical data have pointed to
the urgent need for the reorganisation and improved
delivery of breast cancer care [4,5].
In its 2003 and 2006 resolutions on breast cancer in the
European Union (EU) and the enlarged EU, respectively,
the European Parliament (EP) called on the EU member
states to create, by 2008, the conditions required for a
25% reduction in average breast cancer mortality and for
reducing to 5% the disparity between EU countries in 5-
year survival [6,7]. Both resolutions also called for the
establishment of a network of certified multidisciplinary
breast centres which essentially meet the core criteria set
by the European Society of Breast Cancer Specialists
(EUSOMA) in 2000 and 2004 in their Requirements of a
specialist Breast Unit [8,9]. These in turn were based on,
inter alia, the key aspects of specialisation and centralisa-
tion of cancer treatment as recommended by the 1995
Calman-Hines report, which proposed a policy frame-
work for commissioning cancer services in the United
Kingdom [10].
In view of the high incidence of breast cancer and the rec-
ognised necessity of providing appropriate multidiscipli-
nary treatment, the management of this cancer can be
considered as a prototypical example of a complete proc-
ess chain ranging from early detection and diagnosis to
treatment and follow-up. Under this aspect, breast cancer
care requires elements of quality management, particu-
larly at the various interfaces along the multidisciplinary
and bisectoral, i.e. in- and out-patient, process chain [4,5].
Moreover, all health care providers in Germany are
required by national law to perform quality assurance,
although certification or other external monitoring of a
complete quality management system (QMS) is not man-
datory [11].
Against this backdrop, and in line with the European pol-
icies to reduce breast cancer mortality, which date back to
the early 1990s, the German Cancer Society (Deutsche
Krebsgesellschaft, DKG), the multidisciplinary German
Society of Senology (Deutsche Gesellschaft für Senologie,
DGS) and other relevant German specialist medical socie-
ties, including the German Society for Gynaecology and
Obstetrics (Deutsche Gesellschaft für Gynäkologie und
Geburtshilfe, DGGG), undertook to develop and imple-
ment a nationwide dual certification programme for
breast centres. Certification means the assessment of an
organisation by an accredited third party to show that the
applicant abides by principles set out in a specific stand-
ard to ensure best practice, conformity with the standard
being attested by a certificate. The planned certification
programme was to involve certification of breast cancer
services on the one hand and certification of a mandatory
QMS on the other [12,11]. In the absence of specific legal
requirements, certification was to be voluntary. Certifica-
tion of service delivery to specific Requirements of Breast
Centres (Fachliche Anforderungen an Brustzentren, FAB)
[13] was to be organised and conducted on behalf of the
DKG and the relevant specialist medical societies by a
newly established, independent organisation for services
related to the certification of cancer centres. Specifically,
the FAB were to be set by the DKG and DGS mainly on the
basis of the two multidisciplinary, evidence-based
national level-3 guidelines [14-16] and the EUSOMA
Requirements [8,9].
Based on the data collected from late 2002 to mid 2008
we aim to show in the following feasibility and proof-of-
concept study that it has proved possible in Germany to
establish a well-accepted, voluntary dual certification pro-
gramme for breast centres that involves both certification
to the purpose-developed DKG/DGS Requirements of
Breast Centres (FAB) by a newly founded, independent
organisation for certification of cancer services delivery,
and certification of a mandatory QMS to ISO 9001 or a
similar standard (KTQ) by German third-party certifying
bodies. We also aim to show that certification has resulted
in the centralisation of breast cancer services and that the
great majority of breast cancer patients today are diag-
nosed and treated at specialist breast centres in Germany.
Moreover, to quantify the quality of breast cancer services
and improvements in the quality of breast cancer care, a
Germany-wide voluntary benchmarking programme was
established in parallel with the certification programme.
Benchmarking is another key instrument for quality assur-
ance and enhancement, and the first results from the ini-
tial 2003–2007 period of the benchmarking programme
have recently been reported by Brucker and associates
[17].
Methods
Study rationale, design and objectives
The present study was conducted under the auspices of the
German Cancer Society (Deutsche Krebsgesellschaft; DKG)
and the German Society of Senology (Deutsche Gesellschaft
für Senologie; DGS) as a prospective, iterative interven-BMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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tional multicentre feasibility study. The study was pro-
spective in that it was conducted to develop a detailed set
of definitive Requirements of Breast Centres based on the
Requirements of a Specialist Breast Unit set by the Euro-
pean Society of Breast Cancer Specialist (EUSOMA) [8,9],
and two multidisciplinary, evidence-based national level-
3 guidelines [16,15,14], and to create and implement a
voluntary certification programme for breast centres in
Germany [11]. The study was interventional in two
respects. Firstly, a collaborative network of breast centres
needed to be established to enable external collection of
data. Secondly, external data collection and breast centre
certification required the establishment of a provider of
certification services for the delivery of specialist (breast)
cancer services that was separate from, and independent
of, the participating clinical institutions. This necessitated
the foundation of an organisation that would be commis-
sioned to conduct programmes for the certification of site-
specific cancer centres on behalf of the DKG and DGS.
The rationale for the present study [4,5] was based on the
following cornerstones:
1. specialisation (a high annual hospital volume of > 150
newly diagnosed breast cancers [18] and a caseload of ≥
50 primary operations/year per breast surgeon [8]);
2. multidisciplinarity [19-22];
3. QMS certification by a third-party certifying body to an
internationally recognised standard such as ISO 9001;
and
4. benchmarking of the quality of breast cancer care [17].
The study followed a design with four, partly overlapping
phases to provide proof of concept for the feasibility and
acceptance of a nationwide voluntary certification pro-
gramme for breast centres in Germany.
Phase I: A set of specific, largely guideline-based Require-
ments of Breast Centres (Fachliche Anforderungen an
Brustzentren; FAB) was to be developed as the basis for the
certification of multidisciplinary cancer services delivery.
Phase II: Pilot certification to the FAB was to be per-
formed for a small number of breast centres in addition to
separate mandatory third-party certification of a previ-
ously implemented hospital quality management system
(QMS).
Phase III: Recertification of the pilot breast centres was to
demonstrate proof of concept for the DKG/DGS pro-
gramme for dual certification of breast centres.
Phase IV: Certification and recertification of other breast
centres in Germany was to extend the proof of concept to
the multicentre level.
The objectives of the present prospective iterative study
were:
￿ to develop a set of Requirements of Breast Centres,
primarily for Germany, under the joint direction of the
German Cancer Society (DKG) and the German Soci-
ety of Senology (DGS) in collaboration with other rel-
evant German specialist medical societies;
￿ to establish an independent organisation that would
co-ordinate certification to the DKG/DGS Require-
ments (FAB) on behalf of the DKG and the DGS;
￿ to create an appropriate procedure for DKG/DGS
certification of breast centres having a mandatory,
third-party-certified QMS;
￿ to build a nationwide voluntary network that would
ultimately encompass all breast centres in Germany
and, later, other countries; and
￿ to demonstrate the feasibility and general acceptance
of the programme, thus providing a proof of concept
for the DGK/DGS certification programme.
The final objective of the study was to show that a nation-
wide certification programme for breast centres would be
associated with much improved guideline compliance
and centralisation of breast services during the period
from late 2002 to mid 2008.
Participating institutions
Specialist breast centres and hospitals with breast care
units focussing on breast cancer care in Germany, Austria
(as of 2003), Switzerland and the partly German-speaking
regions of northern Italy (both as of 2006) were invited to
participate on a voluntary basis in an independent, exter-
nal, scientifically based certification programme jointly
developed by the German Cancer Society (DKG) and the
German Society of Senology (DGS) and in collaboration
with independent certifying bodies (see below).
DKG/DGS Requirements of Breast Centres (FAB)
Starting from an early checklist of basic requirements in
2000, a detailed set of requirements was to be developed
by the DKG, DGS and other relevant specialist medical
societies. These DKG/DGS Requirements of Breast Centres
(Fachliche Anforderungen an Brustzentren; FAB) were to
include the EUSOMA Requirements [8,9] as well as items
derived from the two relevant multidisciplinary, evidence-BMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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based national level-3 guidelines [15,16] and additional
items based on German legal requirements.
Quality management system
Each participating breast centre was to implement and
maintain a quality management system (QMS) for which
mandatory certification to ISO 9001 or a similar standard
(KTQ) was to be obtained from a German third-party cer-
tifying body.
DKG-commissioned certification service provider
An independent DKG-commissioned certification service
provider (DKG-CSP) was to be created for the purpose of
providing all necessary services and organisational tasks
related to the certification of cancer services delivery,
including consultancy, organising training courses for the
specialist auditors and the conduct of audits.
Certification procedure
The details of a procedure were to be work out which
would result in dual certification of applicant breast cen-
tres to the DKG/DGS Requirements (FAB) as regards
breast services delivery and to ISO 9001 (or similar, e.g.
KTQ) as regards the mandatory QMS.
Data collection and analysis
Data collection was based on voluntary registration of
breast cancer treatment institutions with the DKG/DGS
certification programme.
Data analysis was performed using standard software,
including Microsoft Access®, Excel® and Word® 2002 and
2003 (Microsoft Corporation, Redmond, WA, USA).
The relevant study data (including date of application for
certification, date of initial certification, date of full certi-
fication and date of recertification) for each participating
breast centre or hospital breast care unit were collected by
the DKG-commissioned certification service provider
(DKG-CSP) on a monthly basis.
Changes in the number of participating centres during the
period from 1 December 2002 to 30 June 2008 were ana-
lysed by descriptive numerical and graphical methods
(tables and graphs) and visual inspection. No statistical
tests were employed.
Results
Phase I
FAB: Starting from a "checklist" catalogue of requirements
in 2000, the German Cancer Society (DKG) and German
Society of Senology (DGS) developed a comprehensive
set of service delivery-related Requirements of Breast Cen-
tres (FAB) in several steps in collaboration with other rel-
evant German specialist medical societies, including the
German Society of Obstetrics and Gynaecology (DGGG).
In April 2003, the FAB received their final form as a ques-
tionnaire to be completed by breast centres as the initial
step in the certification process. A revised FAB question-
naire was made available online in August 2006. Table 1
presents in condensed form the overall structure of the
2006 version of the questionnaire and its essential items.
This version of the questionnaire encompassed 185 single
items. Of these, 84 were quantifiable items, with 49 repre-
senting quantitative minimum requirements.
In brief, the DKG/DGS Requirements of Breast Centres
(FAB) [13] comprise a catalogue of cancer services require-
ments, i.e. clinical practice and service implementation
criteria, which cover the following aspects:
￿ general criteria (multidisciplinarity, access to sup-
port groups, psychosocial care),
￿ staffing (criteria relating to different disciplines such
as radiology, nuclear medicine, surgical disciplines,
radiotherapy, pathology, oncology),
￿ national level-3, evidence-based guidelines for serv-
ice delivery, and
￿ documentation, data analysis and outcome.
The FAB are reviewed, revised and developed further on a
regular basis by the DKG-appointed Certification Com-
mittee, whose main task is to ensure that the FAB reflect
current guidelines and other, e.g. legal, requirements.
QMS: All participating breast centres maintained a QMS
that was certified to an internationally recognised stand-
ard, usually ISO 9001 (71%), or the German KTQ stand-
ard for health care providers http://www.ktq.de.
DKG-CSP: During an initial phase, audits were conducted
by DKG/DGS-appointed specialists, senior doctors from
hospitals other than the applicant breast centre, and certi-
fication was granted by the DKG. In 2003, the DKG
founded a separate certification service provider, OnkoZ-
ert GmbH, Ulm, Germany, (referred to here as the DKG-
CSP) to manage the entire certification process, i.e. to
handle the applications, organise courses to train Special-
ist Expert auditors, schedule the audits and issue the cer-
tificates on behalf of the DKG and the relevant specialist
medical societies, e.g. the DGS for breast centres. The
DKG-CSP became fully operational as a separate service
provider in December 2004.
The DKG-CSP operates under the supervision of the DKG
and the relevant specialist medical societies and acts on
the decisions of the Certification Board.BMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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Table 1: The DKG/DGS Requirements of Breast Centres (FAB): structure and general overview
1 General information on the breast centre
Structure of the network; tumour board/treatment planning; collaboration with doctors in private practice; access to support groups; 
psychosocial and psycho-oncological care; aftercare and follow-up; patient involvement; scientific research activities
2 Information on radiology services
Mammography equipment; stereotactic biopsy requirements; magnetic resonance imaging; breast ultrasound; radiography assistants; specialist 
radiologists (min. 2 names); basic and continuing medical education; quality circles (≥ 4 minuted meetings per year); number of mammograms 
read (> 2000/year (per breast)); specimen radiography; percutaneous biopsies (number); image-guided localisations (number); ductography 
(galactography) (images/year); description of techniques and procedures used; guidelines (fulfilment of requirements)
3 Information on nuclear medicine services
Medical laboratory assistant (min. 2 names); specialist doctors (min. 2 names); continuing education for medical and paramedical staff; quality 
circles (≥ 4 minuted meetings per year); number of bone scintigrams (1st/3rd year requirement: > 200/> 400); sentinel node biopsies (SNBs, 
(1st/3rd year requirement: > 20/> 30); SNB detection rate (1st/3rd year requirement: > 80%/> 90% (gamma probe guided)), (1st/3rd year 
requirement: > 80%/> 90% (scintigraphy; optional)); quality control testing of equipment; fulfilment of relevant level-3 guideline requirements
4 Information on surgical treatment – surgery – gynaecology – specialist breast services
Inpatient care; description; sufficient time for patients to consider treatment choices between core biopsy results and surgery (max. 14 days); 
operating theatre (OT) for breast surgery (min. 1 OT); continuing education of nursing staff; nursing staff (min. 2 full-time nurses/100 primary 
cases); specialist cancer nurse (min. 1); basic and continuing education for medical and paramedical staff; specialist doctors for the breast centre 
(min. 2 names); breast surgeons (min. 2 with specialist qualifications); details of breast surgeons' qualifications; quality circles (≥ 4 minuted 
meetings per year); number of primary breast cancers per surgeon: > 50 per year; total number of surgical procedures (axillary dissections (1st/
3rd year requirement: > 85%/> 95%), revision procedures (< 5%), postoperative wound infections (2.5-max. 5%)); number of operations for 
breast tumours (benign, precancerous, primary, recurrences), primary carcinomas per centre per year (1st/3rd year requirement: > 100/> 150); 
number of pTis (1st/3rd year requirements: > 10%/> 15%); number of benign/malignant open biopsy findings; postoperative specimen 
radiography of microcalcifications after preoperative marker placement > 95%; rate of breast-conserving surgery (1st/3rd year requirement for 
pT1: > 50%/> 70%); mastectomy rate (1st/3rd year requirement for pT1: < 50%/< 30%); primary surgical treatment involving 1, 2, 3 or > 3 
procedures, and rate of R1 resections; mean number of removed lymph nodes > 10 (in accordance with the guideline); breast reconstruction 
(responsibilities, details of collaboration if performed elsewhere, type of reconstruction procedure, surgeon's qualifications, general 
reconstructive surgery requirements); patient information and discussion of treatment options; breast clinics at least once weekly for early 
detection, treatment planning, advice to outpatients considering reconstruction, advice on benign breast disease, inflammation and impaired 
development (waiting times for clinic appointments/consultation < 2 weeks/1 hour); biopsies for histology (results after < 6 days); histological 
confirmation of tumour status (by core biopsy) in 90% of palpable and 70% of nonpalpable tumours; communication of tumour status diagnosis 
within < 1 week; documentation of the number of patient who refuse treatment; side-effects of treatment; knowledge and implementation of 
level-3 guideline.
5 Information on radiotherapy services
High energy radiotherapy equipment (minimum specifications, other requirements); description of radiotherapy techniques (guideline-
concordant dose regimen); radiography assistants (min. 2); continuing education for medical and paramedical staff; quality circles (≥ 4 minuted 
meetings per year); specialist radio-oncologists (min. 2); aftercare and follow-up; documentation/tumour assessments, reactions to radiotherapy 
(acute, subacute, late); compliance with level-3 guideline for treatment; written patient information during and after radiotherapy; applicable 
level-3 radiotherapy guidelines
6 Information on pathology services
Specialist pathologists (min. 2 names); qualifications: details of expertise in breast histology and cytology; continuing education for medical and 
paramedical staff; external quality assurance; quality circles (≥ 4 minuted meetings per year); specialist experience: examination of 200 routine 
histological specimens from breast disease patients and 3000 histological specimens; rapid frozen sectioning (infrastructure, cryostat); number 
of rapid frozen sections performed per year; time to result; lymph node examination; specimen storage time: paraffin blocks ≥ 10 years, wet 
specimens ≥ 4; weeks; gross, microscopic and immunohistochemical examination and diagnosis; standardised processing for gross examination 
according to level-3 guideline; pathologist's report on breast specimens (except diagnostic core biopsies) must contain guideline-specified 
details for the gross pathology report microscopic examination; resection/safety margins; pT and pN status for > 95% of invasive tumours; 
measurable receptors (hormone receptors (> 95%), HER2/neu (> 95%), FISH analysis if necessary)
7 Information on oncology services (gynaecology, medical oncology, inpatient/outpatient services)
Specialist oncologist (internist or gynaecologist, experienced in chemotherapy (≥ 800 treatment cycles) and endocrine, immunological, adjuvant, 
palliative and supportive therapy and treatment of side effects); quality circles (≥ 4 minuted meetings per year); continuing education for medical 
and paramedical staff; ≥ 50 breast cancer chemotherapies/year per treatment unit or partner, or ≥ 200 chemotherapies/year for various 
cancers; provision of inpatient and outpatient chemotherapy; appropriate infrastructure; min. 2 chemotherapy rooms; description of facilities 
for supportive/palliative care; description of treatment phases during chemotherapy (initiation to termination); provision of information to 
patients and dialogue with patients; compliance with relevant level-3 guideline requirementsBMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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Certification procedure: During the initial phase from
November 2001 to June 2003, test and pilot certifications
were performed. After the inception of the DKG-CSP, the
current procedure was implemented in July 2003. A sche-
matic representation of the dual certification procedure
for breast centres is shown in Figure 1. The procedure
begins with the applicant breast centre submitting to the
DKG-CSP an enquiry form requesting initiation of the cer-
tification process. The DKG-CSP will then estimate the
effort and cost of certification, upon which the breast cen-
tre will file a formal application and submit the com-
pleted FAB questionnaire. This information is assessed for
FAB compliance by DKG-CSP-trained Specialist Experts,
who will subsequently endorse the application or suggest
necessary changes in preparation of the certification audit.
The Specialist Experts will then arrange an on-site prelim-
inary meeting at the applicant breast centre to discuss
unclear items or critical issues that might endanger certifi-
cation. Certification is then scheduled according to an
audit plan. At the actual, usually two-day certification
8 Tumour documentation/outcome quality
Details of tumour documentation system (TDS), which must contain complete patient and treatment details for ≥ 3 months prior to initial 
certification, details of treatment stage, data for cancer registries; guideline-compliant data sets; data collection by calendar year and 
certification period; responsible documentation manager; 50% position/breast centre for data collection-related tasks; data selection options 
must include by year, patient's name, diagnosis, type of treatment, date of recurrence/metastasis, survival data; outcome quality indicators: 
disease-free survival (DFS), overall survival (OAS), date and proportion of recurrence per stage and type of surgery (breast-conserving surgery 
(BCS) vs. mastectomy); date and location of metastasis; quality of life; Kaplan-Meier curves (local recurrence-free survival and OAS, by relevant 
prognostic groups, survival from progression); comparisons with other breast centres; multivariate analyses; appraisal of achievement of TDS 
objectives (transparency); DFS and OAS must be available at recertification every 3 years; 10-year recurrence rates for mastectomy/BCS: < 
10%/< 15%; completed questionnaire and relevant process descriptions must be available at initial certification; documented data must be 
accessible; uses for TDS data: at least once-yearly in-house analysis of the data, centre-specific and comparative analyses, analysis-based 
improvements; archiving of results (data analysis, appraisal, actions); discussion of results with the main collaborating partners and the breast 
centre network as a whole; compliance of data with guideline requirements; responsible physicians' awareness of their data compared with 
other centres and the literature (quality of data, quality of care); appraisal of flexibility of documentation
The FAB of 2006 encompass 185 items from eight main areas. Applicant breast centres need to (1) describe existing facilities, resources and 
procedures and (2) meet specified requirements in order to attain initial or full certification and recertification.
Table 1: The DKG/DGS Requirements of Breast Centres (FAB): structure and general overview (Continued)
Dual certification of breast centres to the DKG/DGS Requirements (FAB) and an accepted QMS standard. Figure 1
Dual certification of breast centres to the DKG/DGS Requirements (FAB) and an accepted QMS standard. 
Adapted from [23] and [11]. DKG = German Cancer Society; DGS = German Society of Senology; QM(S) = quality manage-
ment (system).
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audit, two Specialist Experts and one expert from the QMS
certifying body will inspect the various departments, facil-
ities and areas of the applicant breast centre that are rele-
vant to multidisciplinarity, and any external partners with
which it collaborates. These experts will also inspect ran-
domly sampled documents and records and interview
staff to verify the information submitted in the FAB ques-
tionnaire. In the event of discrepancies, the breast centre
is given up to three months to rectify these prior to re-
audit. The on-site certification audit is concluded with a
final discussion, at the end of which the experts inform
the breast centre whether they will recommend that the
DKG/DGS Certification Board endorse certification and
whether the QMS requirements have been met. Once the
Certification Board has endorsed the application and
QMS certification has been obtained, the DKG Certifica-
tion Board will issue the DKG/DGS Certificate. To moni-
tor FAB compliance, annual on-site audits based on up-
dated FAB questionnaire data are conducted randomly by
Specialist Experts, with a particular focus on comments,
suggestions and issues from previous audits. The various
audits and re-audits are conducted by different Specialist
Experts.
The DKG/DGS Certificate, including the QMS certificate,
is valid for three years. The breast centre then needs to
apply for recertification, which involves an FAB-based
audit similar to the initial procedure, and QMS certifica-
tion to the ISO 9001 or the KTQ standard [11,23].
In summary, DKG/DGS certification of breast centres is a
two-part procedure involving certification of the manda-
tory hospital QMS to the ISO 9001 or the KTQ standard,
and certification of service delivery to the DKG/DGS
Requirements of Breast Centres, the FAB. The DKG/DGS
Certificate expires after three years, necessitating recertifi-
cation according to the same basic procedure.
Phase II
Proof of concept: The first pilot certification of a breast
centre to both ISO 9001 and DKG/DGS Requirements,
then still the "checklist" in its 4th revision, was achieved
in December 2002. The dual certification procedure in its
present form was established in July 2003 after the 5th
revision of the "checklist", which was then renamed to
FAB.
Figure 2 summarises the certification-related data col-
lected by the DKG-CSP since it became fully operational
in November 2004.
Phase III
Final proof of concept was provided by the first recertifi-
cations. At the end of 2005, the first two DKG/DGS-certi-
fied breast centres successfully completed recertification
after their first three-year certification. By mid 2008, 79 of
80 breast centres due for recertification had successfully
completed the process. One breast centre failed to meet
the recertification requirements in 2007 and was therefore
excluded from further participation in the DKG/DGS cer-
tification programme.
Phase IV
Further results: From the end of 2004 to 30 June 2008,
the overall number of certified breast centres increased
from 57 to 175, while the number of single-site certified
breast centres rose from 53 to 136 (cf. Figure 2). In relative
terms, the proportion of single-site breast centres dropped
from 93% (53/57) to 78% (136/175) from the end of
2004 to mid 2008. This was due to rising numbers of 2- to
4-site centres joining the DKG/DGS dual certification pro-
gramme. During the same period the number of certified
breast centres with 2, 3 or 4 sites increased from 4 to 39,
the vast majority of which (36/39; 92%) were 2-site cen-
tres.
During the 3.5-year period from 1 January 2005 to 30
June 2008, the mean number of primary cases per breast
centre in the year preceding certification rose by 6% from
196 to 208, while the total number of primary breast can-
cers treated at breast centres with dual ISO 9001 (or KTQ)
and DKG/DGS certification in Germany during the year
preceding certification increased 3.5-fold from 11,152 to
38,485 (data not shown), representing a rise from 22 to
77% (see Figure 2) of an estimated 50,000 primary breast
cancers per year.
Discussion
Breast cancer continues to be the most common cancer in
women, both in Germany and throughout the world
[24,25]. With more than 50,000 women estimated to be
diagnosed annually with breast cancer, Germany ranked
ninth in a 2002 comparison of 24 European countries
[25].
In recent years, and in line with European policies [6,7],
health policies in Germany have emphasised the increas-
ing importance attributed to breast cancer [26,27]. Efforts
have been directed towards developing and implement-
ing structured, intersectoral quality management pro-
grammes aimed at optimising breast cancer care to reduce
inappropriate care and the over- and underprovision of
care [28].
Until the initiation of the present study in 2002, the term
"breast centre" was not in any way properly defined or
protected in Germany. Therefore the German Cancer Soci-
ety (DKG) and the German Society of Senology (DGS), in
collaboration with other relevant specialist medical socie-
ties, jointly undertook to develop and implement a defin-BMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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itive certification programme for multidisciplinary breast
centres [12] with a view to establishing a prototypical cer-
tification programme for other multidisciplinary site-spe-
cific cancer centres such as colon and prostate centres
[29,30].
Phase I of the present study was successful in developing a
set of specific Requirements of Breast Centres (Fachliche
Anforderungen an Brustzentren; FAB) which were largely
based on the two national level-3, evidence-based guide-
lines on early detection [16] and the diagnosis and treat-
ment of breast cancer [15,14], but were also compatible
with the EUSOMA Requirements of a Specialist Breast
Unit [8,9]. Compared with the EUSOMA Requirements,
however, the FAB are more comprehensive in terms of the
number of individual requirements a breast centre must
meet. The number was even increased in 2006 from 173
items to 185 single items (including 84 quantifiable
requirements and 49 quantifiable minimum require-
ments) as compared with 67 EUSOMA items (including
10 quantifiable minimum requirements). This difference
in detail and comprehensiveness is likely due to the
EUSOMA requirements representing an international
effort that needs to take account of, and bridge, the differ-
ences between national healthcare systems. The differ-
ences between the DKG/DGS and EUSOMA requirements
have been discussed in detail elsewhere [11]. Generally
speaking, the German FAB can be considered a further
DKG/DGS-certified breast centres: applications, certified centres and sites, and primary cases/year treated at certified centres Figure 2
DKG/DGS-certified breast centres: applications, certified centres and sites, and primary cases/year treated at 
certified centres.
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development and expansion of the EUSOMA Require-
ments.
This first phase of the study was also successful in that all
participating centres subjected their legally required qual-
ity management system (QMS) to third-party certification
with annual audits. In this respect the DKG/DGS certifica-
tion programme differs from EUSOMA certification,
which does not require that breast centres have a QMS.
Finally, study phase I was successfully concluded with the
founding of a certification service provider by the German
Cancer Society (DKG) to manage the organisation and
conduct of the certification process, and with the develop-
ment of the dual certification procedure involving QMS
certification to an internationally accepted standard such
as ISO 9001 in addition to certification to the FAB require-
ments developed by the DKG/DGS. The requirement of a
QMS as such, and even more so, a third-party-certified
QMS constitutes a significant difference between the
DKG/DGS and the EUSOMA certification programmes.
Moreover, DKG/DGS certification involves closer, annual
auditing and recertification at 3-year intervals as opposed
to the EUSOMA system with 5-year recertification.
As of mid 2008, 22 German breast centres and two Swiss
breast centres had been granted EUSOMA Initial Certifica-
tion but none had attained EUSOMA Full Certification
requiring five years of audit data, or Re-Certification
according to the procedure outlined in the revised version
http://www.eusoma.org/doc/EusomaCertificationDocu
ment.pdf of the relevant 2006 EUSOMA position paper
[31]. By contrast, as of 30 June 2008 the number of breast
centres with dual certification to ISO 9001 and the DKG/
DGS FAB was 175, indicating that the programme has rap-
idly gained wide acceptance since its inception in 2002.
Phase II of the study, i.e. the pilot certification of a small
number of breast centres to the FAB in conjunction with
separate mandatory third-party certification of a previ-
ously implemented QMS, was also completed success-
fully.
Phase III similarly demonstrated successful proof of con-
cept for the DKG/DGS certification programme by com-
pleting recertification of the pilot breast centres.
Phase IV finally extended the proof of concept to the mul-
ticentre level by achieving certification and recertification
of numerous other breast centres in Germany, the total
number of DKG/DGS-certified breast centres reaching
175 by mid 2008.
The results of the present study thus demonstrate the fea-
sibility and general acceptance of the voluntary dual certi-
fication programme for breast centres initiated and
implemented under the auspices of the DKG and the DGS
as one major strategy to improve quality assurance in
breast cancer services in Germany.
The cornerstones of the current approach to quality assur-
ance in cancer services advocated by the DKG, the DGS
and other relevant specialist medical societies in Germany
today are multidisciplinarity, specialisation, centralisa-
tion and benchmarking, with voluntary certification rep-
resenting the DKG's official "seal of quality".
Multidisciplinarity, in the prototypical case of breast cancer,
is based on the rationale to give all women with this dis-
ease access to all areas of expertise necessary to offer them
the best possible care throughout all phases of their treat-
ment.
Specialisation in the broader sense involves the provision
of multimodal and individualised diagnostic and thera-
peutic strategies. In the narrower sense specialisation is
defined as a surgeon's caseload within a fixed time period.
A significant body of evidence supports the conclusion
that the overall survival rate increases with multidiscipli-
nary care and the level of surgeon specialisation, leading
to declines in both mortality and morbidity [18,19,32-
37]. In addition to hospital volume, another important
parameter is annual surgical caseload. Sainsbury et al.
showed that 5-year survival from breast cancer was signif-
icantly better for surgical caseloads > 30 cases/year in con-
junction with a full range of treatment options [32].
Similarly, Stefoski Mikeljevic and associates more recently
found that patients treated by low-workload surgeons had
poorer 5-year survival than those treated by surgeons with
annual workloads of > 50 new patients [38]. Professional
organisations have also included recommendations for
minimum caseloads of breast cancer patients in their
guidelines. The European Society of Breast Cancer Special-
ists (EUSOMA), for instance, requires that surgeons at spe-
cialist breast units personally perform primary surgery on
at least 50 newly diagnosed breast cancers per year but
does not base this figure on any published evidence [8,9].
Also, it is gradually emerging from the literature that
multidisciplinarity – but only in the context of breast can-
cer – appears to be more important than surgeon's special-
isation.
Centralisation of breast cancer treatment in hospitals that
treat a minimum number of breast cancer cases per year
can also significantly improve survival rates. In a study of
the 5-year survival rates of breast cancer patients from 266
hospitals in New York State, Roohan and associates [18]
found that, compared with "high volume hospitals" per-
forming 150 surgeries/year, the mortality risk associated
with treatment in "very low volume hospitals" (< 10 sur-BMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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geries/year) was 60% higher, whereas in "low volume
hospitals" (11–50 surgeries/year) and "moderate volume
hospitals" (51–150 surgeries/year) the mortality dropped
to 30% and 19%, respectively. In this context it should be
critically remarked that the study by Roohan et al., to our
knowledge, is the only source in the pertinent literature to
provide evidence-based support for a minimum annual
hospital volume of 150 primary breast cancers. More
recently a Canadian study by Hébert-Croteau and collab-
orators [39] confirmed for 7-year survival from breast can-
cer that annual hospital volumes of 100 new cases were
associated with better survival rates than lower hospital
volumes. In Austria, a negative effect on survival rate was
found in patients treated at small departments [40]. More-
over, patients treated at a hospital located less than 10
miles from their homes were found to have a 10% higher
mortality risk and those who travelled more than 10 miles
were more likely to travel to high-volume hospitals [18].
Centralisation also offers better opportunities for clinical
studies, which have been shown to improve outcomes,
e.g. in Austria [41]. Further evidence of the benefits of cen-
tralisation has been found in other countries, e.g. in Eng-
land [36].
These findings prompted a major reassessment of the
organisation of the provision of treatment. The interna-
tionally accepted goal now is centralisation or, failing this,
the establishment of tightly co-ordinated networks of can-
cer services providers capable of multidisciplinary co-
operation with a high degree of specialisation and maxi-
mum quality assurance. The European Parliament sees
specialised breast centres as a crucial factor in the effort to
reduce the mortality rate by up to 25% and therefore
called for the necessary basis to be created for breast cen-
tres to be introduced by 2008 [6,7]. Multidisciplinarity is
reportedly associated with an 18% reduction in mortality
provided that all specialists cooperate optimally [35]. This
is due to the fact that surgical treatment of breast cancer,
at least when it comes to mastectomy, is less complex and
sophisticated than surgery for ovarian cancer or colon
cancer. In the latter case, for example, recent literature
analyses have shown short-term outcome and long-term
survival to depend on surgical and hospital caseload
[42,43]. Hence the hypothesis emerges in all discussions
on the subject that it is surgical caseload that matters in
colon and ovarian cancer whereas in breast cancer the cru-
cial factor is the caseload of the whole specialist team,
including the radiologist, pathologist, surgeon, oncologist
and radio-oncologist.
Costs and economic viability, however, are another fun-
damental factor to be considered when demanding cen-
tralisation of breast cancer care in high-volume specialist
breast centres. Centralisation implies that a sufficiently
high caseload can be generated to enable a "centre" to
provide adequate structural and process quality in terms
of both infrastructure and financial means to allow all rel-
evant specialists involved in the diagnosis and treatment
of breast cancer to work together under one roof. To what
extent the initially high costs of this new evidence-based
standard and the associated quality management systems
will be feasible Europe-wide and in what time frame, still
remains to be clarified. An economic analysis by Pagano
et al. [44] estimated that to justify the economic invest-
ment, multidisciplinary breast cancer centres must
achieve a minimum annual volume of 200 newly diag-
nosed cases of breast cancer. Similarly, EUSOMA also calls
for an annual caseload of at least 150 newly diagnosed
cases of primary breast cancer in order to ensure cost effec-
tiveness and maintain the expertise of specialised multi-
disciplinary teams [8,9]. The greatest cost factor would
appear to be that associated with multidisciplinarity, in
particular the availability, at short notice, of all necessary
disciplines. These estimates and requirements are in stark
contrast with calculations and considerations published
by Beckmann and associates [45,46,29,30] who argue that
breast cancer centres in Germany are not economically
viable without substantial cross-subsidisation from other
health care services, e.g. night duties and obstetric services
provided by gynaecologists. In the medium term, cost-
benefit analyses and outcome data will be needed to
decide on the economic viability of breast centres.
Benchmarking the quality of breast cancer care, lastly, is the
final cornerstone in current voluntary endeavours in Ger-
many to implement quality assurance in breast cancer
services and thus to optimise the quality of diagnosis and
treatment. Therefore the DKG/DGS certification pro-
gramme itself also requires the collection of structure-,
process- and treatment-related data. Each participating
breast centre is assessed on the basis of these data and has
to demonstrate improvements at the yearly interim audits
and the three-yearly recertification audits. The progress
achieved within a voluntary programme for benchmark-
ing the quality of breast cancer care in Germany, which
was developed and implemented in parallel with the
present certification programme, has been reported else-
where [17].
The potential limitations of the present study could include
the following. Fundamental criticism levelled at the cen-
tralisation of breast cancer treatment at large cancer hos-
pitals and the subsequent certification of these breast
centres concerns the fact that no definitive measures exist
as yet to demonstrate the advantages of this system. Fur-
thermore, the differences between the various treatment
modalities at the different large centres are likely to be
small, possibly even statistically nonsignificant. Therefore
it may never be possible to obtain conclusive evidence of
differences in long-time survival and recurrence rates. ItBMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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may well be that EUSOMA and all the certification spe-
cialists will never be able to prove their case. Outcome
quality would need to be measurable using these end-
points, just as structural and process quality can be
assessed via quality management manuals. However, it is
unlikely that comparisons at the level of individual breast
cancer centres will be possible before 10-year data become
available. Hence such comparisons of centres may yet
prove very difficult, if not impossible. As demonstrated
with regard to benchmarking the quality of breast cancer
care [17], outcome quality can so far only be measured
indirectly by using surrogate parameters under the general
assumption that better short- to medium-term structural
quality and process quality will result in improved long-
term outcome quality. In other words, the currently used
surrogate parameters are also, or simply, measures of
guideline compliance that the specialist teams introduce
to the individual centres on the basis of structural and
process quality, and multidisciplinarity.
As regards guideline compliance, DKG/DGS certification,
unlike EUSOMA certification, involves an accurate assess-
ment of guideline compliance by independent Specialist
Experts on the basis of each centre's individual quality
management manual. Such audits by Specialist Experts
can subsequently be certified by impartial, third-party ISO
certification experts. Essentially, the audits of guideline
compliance are underpinned by available surrogate
parameters for benchmarking.
The maintenance and further development of a quality
management system (QMS) at a breast centre initially
requires substantial investments in terms of funds, staff
and extra administrative time. Moreover, the benefit of
these quality assurance measures does not become evi-
dent to a team until they have been in place for some time
and the quality management tasks become an integral
part of the hospital routine. This large initial investment,
however, is offset by the team's growing skill in imple-
menting the QMS and the systematic optimisation of the
treatment procedures, which eventually become evident
to all, not least due to increasing numbers of patients. This
system enables a centre to present its statistics and effi-
ciency to the public and compete with other centres.
According to the DKG/DGS certification procedure,
smaller centres can undergo initial, first-year certification
with approx. 100 new cases of primary breast cancer.
However, in addition to the general increase in standards
these centres are expected to meet in order to achieve full
certification after three years, they must also increase the
annual number of new cases of primary breast cancer to at
least 150.
Future prospects
The German Cancer Society (DKG) recently presented an
overall plan for the long-term development of cancer serv-
ices in Germany [47]. Following the prototypical example
of the breast centres, further site-specific multidisciplinary
cancer centres are currently being set up and applying for
voluntary DKG certification. These include centres for
colon, prostate, lung, skin and gynaecological cancers.
The first colon, prostate, gynaecological and skin cancer
centres received DKG certification in March 2006,
November 2007, May 2008 and January 2009, respec-
tively.
These site-specific cancer centres form the lowest rung of
a three-tier service structure. The second level will consist
of larger, intermediate-level cancer centres comprising
several site-specific cancer centres. The third and highest
level in this model for the provision of quality-assured
cancer services is that of the "comprehensive cancer cen-
tres" (CCCs). These will be responsible for research, forg-
ing close links between preclinical research and clinical
oncology. Based on the American model, the CCCs com-
bine the tasks of both the site-specific cancer centres and
the general cancer centres.
Conclusion
Nationwide voluntary certification of breast centres is fea-
sible and well accepted in Germany. Dual certification of
breast centres that involves certification of breast services
to a set of guideline-derived requirements (FAB) in con-
junction with separate, voluntary, third-party certification
of a legally required quality management system can serve
as a model for other multidisciplinary site-specific cancer
centres.
The DKG/DGS certification procedure for multidiscipli-
nary breast centres in Germany has, in fact, already
become the model scheme for quality assurance and cen-
tralisation in the broader field of oncology. While the goal
is now well advanced of establishing a nationwide net-
work of certified breast centres, the important next step for
the centres will be to achieve recertification, since this
demands even higher standards. Beyond that, certified
breast centres play an important role within broader col-
laborative networks which include gynaecologists work-
ing in private practice, mammography screening centres
and health professionals in associated disciplines.
The promotion of quality in cancer services at both the
national and European level will remain an important
task for multidisciplinary and specialist medical societies
in the immediate future.BMC Cancer 2009, 9:228 http://www.biomedcentral.com/1471-2407/9/228
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